MYOPIC CHOROIDAL NEOVASCULAR MEMBRANES TREATED WITH RANIBIZUMAB IN COLOMBIAN POPULATION

Purpose : the aim of this study was to describe the characteristics of myopic choroidal neovascular membranes of hispanic subjects treated with a loading dose of Ranibizumab (Lucentis®) Methods : This is a non-randomized prospective observational case study. Five eyes of 5 patients with naive CNV secondary to pathological myopia were recruited for the study. Demographic features, basal best-corrected visual acuity, grade of myopia, angiographic and tomographic features were obtained at baseline. A loading dose of three monthly Ranibizumab (Lucentis®) inections were given to the recruited subjects. After completion of the loading dose, a complete ophthalmological evaluation, angiography and spectral domain optical coherence tomography (SD-OCT) were obtained subsequently at six and twelve months of follow-up. Results : The mean age of patients was 45 years. The mean  spherical equivalent refractive error was -13.85. At baseline, the mean number of letters was 61.4 and at follow-up to 12 months the mean number of letters was 73.2. The central foveal thickness and subfoveal choroidal thickness decreased in all cases. After loading dose there was no persistent nor recurrent leakage from treated CNV on fluorescein angiography. FAF evidenced an increase in the area of atrophy, with an special circle pattern around the CNV. Conclusions : This study showed a functional and morphologic improvement at 12 months in five Colombian subjects treated with a loading dose of 3 Ranibizumab monthly injection.